Commercial Model Innovation Key To Lowering China Compliance Risks
This article was originally published in PharmAsia News
Executive Summary
Balanced scorecards, big data, and platform strategies are among the new tools being employed by pharma companies ramping up compliance and lowering risks in China, where market access remains challenging and pricing pressures persistent. Such commercial model innovation should also improve physician interaction while providing new medical solutions, said executives at a recent RDPAC gathering in Beijing.
You may also be interested in...
2016 Review: Pricing, R&D Issues Dominate China Commercial Arena
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.
Winter Olympics Test China's 'Zero COVID' Limits, Treatment Constraints
Amid China’s increasingly inward-looking and dual circulation economic policies, the Beijing Winter Olympics provide rare insight into policymakers’ handling of a global event.
Soft Capsule, Hard Truth: Will Chugai Lawsuit Usher In New Era Of China Patent Linkage?
Few drug patent infringement cases go to court in China, where a murky and lengthy process deters many from pursuing litigation. But a newly enacted Patent Law with patent linkage provisions is spurring a rise in infringement lawsuits, with one recent case involving a major Japanese pharma firm underscoring the remaining challenges.